Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Inclusion Criteria: * Subjects with acute ischemic stroke, aging ≥ 19 * Confirmed to have acute anterior circulation cerebral artery occlusion in intracranial internal carotid artery (IICA) or middle cerebral artery (MCA) M1 segment by CT or MR angiography. * National Institutes of Health Stroke Scale(NIHSS) is 6\~30 before endovascular recanalization therapy (ERT) * Subject who is reperfused with 2b or 3 stages of thrombolysis in cerebral infarction (TICI) (However, if angiography is conducted for thrombectomy after IV tPA treatment and the effect of tPA results in TICI 2b-3 reperfusion, the subject can participate) * Subject who can administer IP within 6.5 hrs of symptom development * Subject who can administer IP within 30 min of vascular reperfusion * Subject who can evaluate MRI within 90 min of vascular reperfusion Exclusion Criteria: * Subject who is contraindicated for endovascular recanalization * Subject who has hypersensitivity to contrast agent or component of investigational product * Prohibited or unable to perform MRI test * Medical history that is related to bleeding * History of hemorrhagic stroke within 6 months of study participation * Subjects with chronic liver disorder * Kidney disorder (Serum creatinine \> 3 mg/dL) * Life expectancy is less than 3 months due to concomitant disease other than stroke * Pregnant or lactating women * Those who have taken tirofiban (anticoagulant agent) during endovascular recanalization therapy * Those who have taken other investigational drugs and/or medical instruments 12 weeks prior to screening * Subject is unable to be followed up * Subject is deemed unable to participate the study in the opinion of the investigator.